Dr. Phillips on Activity With Acalabrutinib Plus Bendamustine/Rituximab in MCL

Tycel J. Phillips, MD
Published: Sunday, Dec 02, 2018



Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.

Efficacy rates, especially in the treatment-naive population, were impressive, with complete response rates greater than 70%. The combination was also deemed to be relatively safe, Phillips says, with adverse events similar between the treatment-naive and relapsed/refractory groups.

 <<< 2018 ASH Annual Meeting


Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.

Efficacy rates, especially in the treatment-naive population, were impressive, with complete response rates greater than 70%. The combination was also deemed to be relatively safe, Phillips says, with adverse events similar between the treatment-naive and relapsed/refractory groups.

 <<< 2018 ASH Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x